Paul Tudor Jones's FOLD Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 168,984 shares of Amicus Therapeutics, Inc. (FOLD) worth $1.33 M, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 35 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in FOLD, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2019, adding 217,276 shares. Largest reduction occurred in Q3 2019, reducing 186,971 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Amicus Therapeutics (FOLD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Amicus Therapeutics (FOLD) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +78,079 | New Buy | 78,079 | $5.96 |
| Q4 2014 | +20,443 | Add 26.18% | 98,522 | $8.32 |
| Q1 2015 | -86,902 | Reduce 88.21% | 11,620 | $10.84 |
| Q2 2015 | +94,736 | Add 815.28% | 106,356 | $14.15 |
| Q3 2015 | -67,621 | Reduce 63.58% | 38,735 | $13.99 |
| Q4 2015 | -38,735 | Sold Out | 0 | $0.00 |
| Q1 2016 | +16,950 | New Buy | 16,950 | $8.44 |
| Q2 2016 | +56,031 | Add 330.57% | 72,981 | $5.45 |
| Q3 2016 | -72,981 | Sold Out | 0 | $0.00 |
| Q4 2016 | +51,290 | New Buy | 51,290 | $4.97 |
| Q1 2017 | -51,290 | Sold Out | 0 | $0.00 |
| Q2 2017 | +12,332 | New Buy | 12,332 | $10.06 |
| Q3 2017 | -12,332 | Sold Out | 0 | $0.00 |
| Q2 2018 | +42,724 | New Buy | 42,724 | $15.61 |
| Q3 2018 | -6,127 | Reduce 14.34% | 36,597 | $12.08 |
| Q4 2018 | +42,898 | Add 117.22% | 79,495 | $9.59 |
| Q1 2019 | -79,495 | Sold Out | 0 | $0.00 |
| Q2 2019 | +217,276 | New Buy | 217,276 | $12.48 |
| Q3 2019 | -186,971 | Reduce 86.05% | 30,305 | $8.02 |
| Q4 2019 | +18,851 | Add 62.20% | 49,156 | $9.74 |
| Q1 2020 | -49,156 | Sold Out | 0 | $0.00 |
| Q3 2020 | +15,596 | New Buy | 15,596 | $14.11 |
| Q4 2020 | +30,546 | Add 195.86% | 46,142 | $23.08 |
| Q1 2021 | +17,150 | Add 37.17% | 63,292 | $9.87 |
| Q2 2021 | -63,292 | Sold Out | 0 | $0.00 |
| Q3 2021 | +12,579 | New Buy | 12,579 | $9.54 |
| Q4 2021 | -12,579 | Sold Out | 0 | $0.00 |
| Q4 2022 | +54,577 | New Buy | 54,577 | $0.01 |
| Q1 2023 | +79,120 | Add 144.97% | 133,697 | $0.01 |
| Q2 2023 | -133,697 | Sold Out | 0 | $0.00 |
| Q3 2024 | +148,354 | New Buy | 148,354 | $10.68 |
| Q4 2024 | +514 | Add 0.35% | 148,868 | $9.42 |
| Q1 2025 | -77,577 | Reduce 52.11% | 71,291 | $8.16 |
| Q2 2025 | +88,206 | Add 123.73% | 159,497 | $5.73 |
| Q3 2025 | +9,487 | Add 5.95% | 168,984 | $7.88 |
Paul Tudor Jones's Amicus Therapeutics Investment FAQs
Paul Tudor Jones first purchased Amicus Therapeutics, Inc. (FOLD) in Q3 2014, acquiring 78,079 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Amicus Therapeutics, Inc. (FOLD) for 35 quarters since Q3 2014.
Paul Tudor Jones's largest addition to Amicus Therapeutics, Inc. (FOLD) was in Q2 2019, adding 217,276 shares worth $2.71 M.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 168,984 shares of Amicus Therapeutics, Inc. (FOLD), valued at approximately $1.33 M.
As of the Q3 2025 filing, Amicus Therapeutics, Inc. (FOLD) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Amicus Therapeutics, Inc. (FOLD) was 217,276 shares, as reported at the end of Q2 2019.